Janus Henderson股票掛鉤穩健收益主動型ETF JELM 深 滬
等待開盤 11-04 09:30:00 美东时间
25.305
+0.076
+0.30%
華盛通- 最 高25.37
- 今 開25.285
- 成交量 4863股
- 最 低 25.285
- 昨 收 25.2291
- 總市值 6554.00万
- 52周最高 28.5958
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 24.099
- 委 比 0.00%
- 總股本 259.00万
- 歷史最高 28.5958
- 量 比 0.45
- 振 幅 0.34%
- 歷史最低 24.099
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma announced the publication of five-year follow-up data from the Olympus study in *Therapeutic Advances in Urology*, highlighting JELMYTO's long-term efficacy in treating low-grade upper tract urothelial cancer (LG-UTUC). Among 41 patients achieving complete response, the median duration of response was 47.8 months, with no progression to high-grade disease observed. The findings support JELMYTO as a durable, kidney-sparing treatment ...
10-28 12:00
UroGen Pharma Announces Settlement And License Agreement With Teva Pharmaceuticals Relating to JELMYTO
This Agreement resolves the patent litigation UroGen initiated in response to Teva's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration ("FDA") seeking approval to market a
06-02 20:02
Janus Henderson's New ETFs Aim To Turn Market Swings Into Steady Income
Janus Henderson launches two new ETFs targeting equity-driven income with downside protection and diversification beyond bonds.
05-01 03:13
